anidulafungin
information and resources from the National Cancer Institute
NCI Thesaurus | anidulafungin
A cyclic lipopeptide echinocandin derivative with antifungal activity. Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus. NCI Thesaurus | anidulafungin
A cyclic lipopeptide echinocandin derivative with antifungal activity. Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus.
|
|
|
|
news articles
Pfizer Receives FDA Approval For EraxisTM To Treat Candidemia, A ... Feb 26, 2006
Medical News Today (press release), Pfizer Inc said today that EraxisTM (anidulafungin) has been approved by the US Food and Drug Administration to treat candidemia, a potentially life ...
Blood-infection drug is approved Feb 26, 2006
Yord.nl, The drug, known generically as anidulafungin, was also approved to treat peritonitis, an inflammation of the membrane lining the abdominal wall, and esophageal ...
Lipitor Patent Win Boosts Pfizer Shares Dec 19, 2005
CBS News ...a cancer drug. The FDA sent Pfizer a letter signaling its intention to approve Anidulafungin, an antifungal drug. Exubera, which ...
|
|
